Avendaño-Solà: Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial

Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial

Avendaño-Solà et al., medRxiv, doi:10.1101/2020.08.26.20182444, NCT04345523 (history)

Avendaño-Solà et al., Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial, medRxiv, doi:10.1101/2020.08.26.20182444, NCT04345523

Sep 2020 Source PDF

Twitter
Facebook

All Studies Meta

Early terminated RCT with 81 hospitalized patients, 38 treated with convalescent plasma, showing lower progression with treatment. NCT04345523 (history).

Important missing comments or errors? Let us know.

risk of death, 88.3% lower, RR 0.12, p = 0.12, treatment 0 of 38 (0.0%), control 4 of 43 (9.3%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 29.

risk of progression, 93.0% lower, RR 0.07, p = 0.01, treatment 0 of 38 (0.0%), control 7 of 43 (16.3%), NNT 6.1, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 29, progression to categories 5-7.

risk of progression, 91.9% lower, RR 0.08, p = 0.03, treatment 0 of 38 (0.0%), control 6 of 43 (14.0%), NNT 7.2, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 15, progression to categories 5-7, primary outcome.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Avendaño-Solà et al., 29 Sep 2020, Randomized Controlled Trial, Spain, peer-reviewed, 36 authors, average treatment delay 8.0 days, trial NCT04345523 (history).

All Studies All Outcomes Submit Updates or Corrections

This Paper Conv. Plasma All

Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.08.26.20182444; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Original Article Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial Authors: C Avendaño-Solà1, A Ramos-Martínez2, E Muñez-Rubio2, B Ruiz-Antorán1, R Malo de Molina3, F Torres4, A Fernández-Cruz2, A Callejas-Díaz2, J Calderón2, C Payares-Herrera1, I Salcedo1, I Romera5, J LoraTamayo6, M Mancheño-Losa6, ML Paciello7, C Villegas7, V Estrada8, I Saez-Serrano9, ML Porras-Leal10, MC Jarilla-Fernández11, JR Paño-Pardo12, JA Moreno-Chulilla13, I Arrieta-Aldea14, A Bosch15, M Belhassen-Garcia16, O López-Villar17, A Ramos-Garrido18, L Blanco19, ME Madrigal-Sánchez20, E Contreras21, E Muñiz-Díaz22, JM Domingo-Morera23, I Casas-Flecha24, M Pérez-Olmeda25, Javier GarciaPérez26, J Alcamí26, JL Bueno5 and RF Duarte 5 for the ConPlas-19 Study Group* *Complete list of the ConPlas-19 study group provided in the Supplementary Appendix Affiliations: 1. Clinical Pharmacology Department. Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Hospital Puerta de Hierro-Segovia de Arana, Madrid, Spain. SCReN Clinical Trials Platform. 2. Infectious Diseases Unit, Department of Internal Medicine. Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. 3. Respiratory Medicine Service. Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. 4. Clinical Pharmacology Department, Hospital Clinic Barcelona, Barcelona, Spain. Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain 5. Department of Hematology. Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain 6. Department of Internal Medicine. Hospital Universitario 12 de Octubre. Instituto de Investigación "i+12" Hospital 12 de Octubre, Madrid,Spain. 7. Department of Hematology. Hospital Universitario 12 de Octubre,Madrid, Spain 8. Infectious Diseases Unit, Department of Internal Medicine.Hospital Universitario Clinico San Carlos, Madrid, Spain. 9. Hematology Service. Hospital Universitario Clinico San Carlos. Madrid, Spain. 10. Infectious Diseases Unit, Department of Internal Medicine, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. 11. Hematology and Hemotherapy Service, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. 12. Division of Infectious Diseases. Hospital Clínico Universitario Zaragoza-IIS Aragón, Spain NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.08.26.20182444; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 13. Servicio de Hematología Hospital Clínico Universitario Lozano Blesa, Zaragoza,Spain 14. Infectious Diseases Department, Hospital del Mar, Barcelona, Spain. 15. Blood Transfusion Service. Hospital del Mar. Consorci Mar Parc de Salut. Banc de Sang i Teixits. Barcelona. Spain 16. Internal Medicine..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit